Tags

Type your tag names separated by a space and hit enter

Urinary gonadotropin peptide in patients with cancer of digestive organs.
Anticancer Res. 1996 Jul-Aug; 16(4A):2041-8.AR

Abstract

Urinary gonadotropin peptide (UGP) has been measured in gynecological and urological cancers, but its usefulness in the diagnosis of cancers of digestive organs has not been investigated. In this report, UGP was measured by sandwich enzyme immunoassay in 311 patients, including 166 patients with cancers of digestive organs and 43 healthy controls. Positive rates of UGP in various cancers of digestive organs were as follows: biliary tract 61.5%, pancreas 61.5%, esophagus 50.0%, liver 38.7%, colon and rectum 24.2%, and stomach 23.9%. The positive rate of UGP in benign diseases was 8.1%, and most false-positive patients were postmenopausal females. Positive rates of UGP were increased at advanced stages of gastric cancers, and UGP was decreased after tumor resection. From these results, it is suggested that UGP can be used as a tumor marker for the cancers of digestive organs.

Authors+Show Affiliations

Department of Internal Medicine, Kanazawa University, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

8712740

Citation

Motoo, Y, et al. "Urinary Gonadotropin Peptide in Patients With Cancer of Digestive Organs." Anticancer Research, vol. 16, no. 4A, 1996, pp. 2041-8.
Motoo Y, Watanabe H, Yamaguchi Y, et al. Urinary gonadotropin peptide in patients with cancer of digestive organs. Anticancer Res. 1996;16(4A):2041-8.
Motoo, Y., Watanabe, H., Yamaguchi, Y., Mouri, I., Fujii, T., Yamakawa, O., Satomura, Y., Okai, T., & Sawabu, N. (1996). Urinary gonadotropin peptide in patients with cancer of digestive organs. Anticancer Research, 16(4A), 2041-8.
Motoo Y, et al. Urinary Gonadotropin Peptide in Patients With Cancer of Digestive Organs. Anticancer Res. 1996 Jul-Aug;16(4A):2041-8. PubMed PMID: 8712740.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Urinary gonadotropin peptide in patients with cancer of digestive organs. AU - Motoo,Y, AU - Watanabe,H, AU - Yamaguchi,Y, AU - Mouri,I, AU - Fujii,T, AU - Yamakawa,O, AU - Satomura,Y, AU - Okai,T, AU - Sawabu,N, PY - 1996/7/1/pubmed PY - 1996/7/1/medline PY - 1996/7/1/entrez SP - 2041 EP - 8 JF - Anticancer research JO - Anticancer Res VL - 16 IS - 4A N2 - Urinary gonadotropin peptide (UGP) has been measured in gynecological and urological cancers, but its usefulness in the diagnosis of cancers of digestive organs has not been investigated. In this report, UGP was measured by sandwich enzyme immunoassay in 311 patients, including 166 patients with cancers of digestive organs and 43 healthy controls. Positive rates of UGP in various cancers of digestive organs were as follows: biliary tract 61.5%, pancreas 61.5%, esophagus 50.0%, liver 38.7%, colon and rectum 24.2%, and stomach 23.9%. The positive rate of UGP in benign diseases was 8.1%, and most false-positive patients were postmenopausal females. Positive rates of UGP were increased at advanced stages of gastric cancers, and UGP was decreased after tumor resection. From these results, it is suggested that UGP can be used as a tumor marker for the cancers of digestive organs. SN - 0250-7005 UR - https://www.unboundmedicine.com/medline/citation/8712740/Urinary_gonadotropin_peptide_in_patients_with_cancer_of_digestive_organs_ L2 - https://medlineplus.gov/gallbladdercancer.html DB - PRIME DP - Unbound Medicine ER -